Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 17/20 | 0.58 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.56 |
| ▸ | PRKACA | P17612 | 4/20 | 0.56 |
| ▸ | CDK2 | P24941 | 4/20 | 0.56 |
| ▸ | GSK3B | P49841 | 4/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.56 |
| ▸ | PIM1 | P11309 | 3/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.56 |
| ▸ | HIPK2 | Q9H2X6 | 3/20 | 0.56 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.56 |
| ▸ | GSK3A | P49840 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.47 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.47 |
| ▸ | JAK2 | O60674 | 3/20 | 0.47 |
| ▸ | PRKCG | P05129 | 3/20 | 0.47 |
| ▸ | CDK1 | P06493 | 3/20 | 0.47 |
| ▸ | MARK3 | P27448 | 3/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4294218 | 0.88 | CDC7 (0.65) | CDC7ROCK2PRKACACDK2GSK3B | |
| SCHEMBL4285222 | 0.86 | CDC7 (0.53) | CDC7ROCK2PRKACACDK2GSK3B | |
| SCHEMBL4297793 | 0.86 | CDC7 (0.53) | CDC7ROCK2PRKACACDK2GSK3B | |
| SCHEMBL27788234 | 0.84 | CDC7 (0.56) | CDC7ROCK2PRKACACDK2GSK3B | |
| SCHEMBL3667784 | 0.78 | ROCK2 (0.65) | CDC7ROCK2PRKACACDK2GSK3B | |
| SCHEMBL3670860 | 0.75 | DYRK3 (0.49) | ROCK2GSK3BCLK4GSK3AMAPK1 | |
| Tert-Butyl Formate SCHEMBL27788235 | 0.74 | CDC7 (0.80) | CDC7ROCK2PRKACACDK2GSK3B | |
| SCHEMBL3668569 | 0.73 | CDC7 (1.00) | CDC7ROCK2PRKACACDK2GSK3B | |
| SCHEMBL3666525 | 0.73 | CDC7 (0.60) | CDC7ROCK2PRKACACDK2GSK3B | |
| SCHEMBL3670938 | 0.72 | CDC7 (1.00) | CDC7ROCK2PRKACACDK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9163007-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-11-20 | — | — | US | disclosed |
| US-8648069-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2167491-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | Abbott Laboratories (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2008154241-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | CDC7 8/4885ROCK2 48/4885PRKACA 178/4885 |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | CDC7 8/4885ROCK2 48/4885PRKACA 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.